The study reported by Kapoor et al in this month’s European Journal of Human Genetics explains the dichotomy between the accelerated pace of discovery and the slow uptake of pharmacogenomics in standard clinical care through a SWOT analysis. A glass can be perceived as being half-full or half-empty. Although the authors predict many positive effects and applications of pharmacogenomics they also present a rather pessimistic view on the status and attitudes toward pharmacogenomics and its implementation in clinical care. However, we, like many others, foresee a much more optimistic future for both the impact of pharmacogenomics and its imminent implementation. van der Wouden CH, Swen JJ, Samwald M, Mitropoulou C, Schwab M, Guchelaar HJ. Eur J Hum Genet. Dec 2016; 1-3.
Read full publication (PDF): VanderWouden_EurJHumGen_Dec2016